News & Updates
Filter by Specialty:
Fenofibrate keeps lid on triglyceride in NASH patients receiving ACC inhibitor
For nonalcoholic steatohepatitis (NASH) patients with hypertriglyceridaemia, treatment with fenofibrate helps reduce the increases in triglyceride levels associated with acetyl-coenzyme A carboxylase (ACC) inhibition, as shown in a study.
Fenofibrate keeps lid on triglyceride in NASH patients receiving ACC inhibitor
13 Jan 2022Long-term statin users at risk of colon cancer
Use of statins does not appear to be chemopreventive against colorectal cancer (CRC), and no significant association exists between total cholesterol level and CRC risk, a study has found. In addition, long-term statin use may increase the risk of colon cancer.
Long-term statin users at risk of colon cancer
13 Jan 2022Can digital health revolutionize IBD management?
Digital health technologies (DHTs) can help lower healthcare utilization and costs but appear to have not enough juice to reduce the risk of relapse, improve quality of life (QoL), and increase treatment adherence in patients with inflammatory bowel disease (IBD), according to a study.
Can digital health revolutionize IBD management?
13 Jan 2022GI symptoms in COVID-19 more prevalent than previously reported
There appears to be a higher prevalence of gastrointestinal (GI) symptoms in hospitalized patients with COVID-19 than previously reported, reveals a recent study.
GI symptoms in COVID-19 more prevalent than previously reported
13 Jan 2022Breakthrough infections with COVID-19 Delta variant linked to lower memory B cell response
The memory B cell response appears to be weaker in vaccinated individuals who develop breakthrough infections with the Delta variant of the coronavirus disease 2019 (COVID-19), according to a new Singapore study.
Breakthrough infections with COVID-19 Delta variant linked to lower memory B cell response
13 Jan 2022Smokers more likely to develop COVID-19 complications
Among patients with COVID-19 infection, those who smoke are at higher risk of developing complications compared with those who do not smoke, according to a study from Malaysia.
Smokers more likely to develop COVID-19 complications
13 Jan 2022Fulvestrant-palbociclib combo pre-progression improves PFS in ESR1+ mBC
Switching to a fulvestrant-palbociclib regimen prior to disease progression after detection of elevated ESR1 mutations in the blood of patients with hormone receptor-positive (HR+), HER2-negative (HER2-) metastatic breast cancer (mBC) who were receiving aromatase inhibitors (AIs) plus palbociclib extended their progression-free survival (PFS), results of the phase III PADA-1 trial showed.